glp-1 agonist home delivery clinics Clinician-Guided Microdosing GLP-1 Medications for Weight Loss

[2] The head-to-head ACHIEVE-3 trial, published in The Lancet in February 2026, compared orforglipron 36 mg to oral semaglutide 14 mg in 1,698 patients with type 2 diabetes over 52 weeks

(Average Weight Loss Breakdown) The clinical trial results for GLP-1 weight-loss treatments show that orforglipron delivers meaningful reductions in body weight, especially at higher doses

patients should consult their GP before use

95% CI, 0.99-1.93)

Back Marks, V, Samols, E (1970) 'Intestinal factors in the regulation of insulin secretion', Advanced Metabolic Disorders , 4, 1-38

until at least 2032, when the first main patent for the drug, held by Novo Nordisk,expires